TRANSGENE

The Phase II study of TG4001 in combination with avelumab did not meet the primary objective of improving progression-free survival in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors. However, a positive efficacy trend was observed in cervical cancer patients, prompting further analysis. Transgene will determine the best path forward for TG4001 after completing a full data analysis.

Transgene to present 24-month follow-up data from Phase I trial of individualized cancer vaccine TG4050 for head and neck cancer at SITC annual meeting in Houston, Nov 6-10, 2024.

L.Z. founded EverImmune Cie, serves as its scientific advisory board president, has a research contract with Pileje, and was on the board of Transgene for 9 years.

S.B., A.D., T.J.F., I.M.G., L.G., R.K.J., G.K., J.M.L., G.V.L., K.P.-J., H.I.S., J.T., R.R.W., M.W., Y.L.W. have disclosed various financial interests, including funding, advisory roles, patents, and equity. C.M.B., E.B., M.W.B., and K.P. declare no competing interests.

Transgene reports 2024 H1 results, highlighting clinical benefits of TG4050 in head and neck cancer, promising antitumor activity of BT-001 in solid tumors, and expected Phase II results for TG4001 in Q4 2024. Financial visibility confirmed until Q4 2025.

DelveInsight's 'Gene Therapy Competitive Landscape 2024' report covers 250+ companies and 300+ therapies, highlighting key players like Candel Therapeutics, SillaJen Biotherapeutics, and Wuhan Binhui Biotechnology. The report assesses gene therapy products by type, stage, route of administration, and molecule type, and includes inactive pipeline products. Notable therapies in development include ABECMA, ADSTILADRIN, and BREYANZI. Recent clinical trials include Sangamo Therapeutics' ST-920 for Fabry disease and Regenxbio's RGX-202 for Duchenne.

Transgene appoints Dr. Emmanuelle Dochy as CMO and Dr. Maurizio Ceppi as CSO to advance cancer immunotherapies and precision medicine, with a focus on personalized therapeutic cancer vaccine TG4050.